Management of colitis
| Overall (n=115)* | PD1 (n=35) | IPI+ PD1 (n=80) | P value | |
| Initial corticosteroid therapy | 0.04 | |||
| Oral steroid | 78 (68.4) | 29 (82.9) | 51 (63.8) | |
| Intravenous steroid | 36 (31.6) | 6 (17.1) | 29 (36.3) | |
| Dose of steroid (max) n (%)† | 0.01 | |||
| ≤50 mg | 16 (14.0) | 9 (26.5) | 7 (8.8) | |
| ≥75 mg | 98 (86.0) | 25 (73.5) | 73 (91.3) | |
| Intravenous steroid (methylprednisolone) | 0.01 | |||
| No | 64 (55.7) | 27 (77.1) | 37 (46.3) | |
| Yes | 51 (44.3) | 8 (22.9) | 43 (53.7) | |
| Duration of steroid (weeks), n (%) | 0.99 | |||
| Median (range) | 10.9 (1.7, 66.1) | 11.3 (1.7, 66.1) | 10.5 (2.1, 57.8) | |
| Infliximab | 0.03 | |||
| No | 55 (47.8) | 22 (62.9) | 33 (41.3) | |
| Yes | 60 (52.2) | 13 (37.1) | 47 (58.8) | |
| Infliximab doses | 0.44 | |||
| Single | 46 (76.7) | 11 (84.6) | 35 (74.5) | |
| Multiple | 14 (23.3) | 2 (15.4) | 12 (25.5) | |
| Further immunosuppression | 0.54 | |||
| No | 102 (88.7) | 32 (91.4) | 70 (87.5) | |
| Yes | 13 (11.3) | 3 (8.6) | 10 (12.5) | |
| Reinitiation of PD1 monotherapy, n (%) | 0.41 | |||
| No | 72 (62.6) | 24 (68.6) | 48 (60.0) | |
| Yes | 43 (37.4) | 11 (31.4) | 32 (40.0) | |
| Recurrence of colitis, n (%) | 0.99 | |||
| No | 99 (86.0) | 30 (85.7) | 69 (86.3) | |
| Yes | 16 (14.0) | 5 (14.3) | 11 (13.8) | |
*Excludes three patients with ipilimumab.
†One patient did not receive any steroid treatment.
IPI, ipilimumab; PD1, programmed cell death protein 1.